Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
121 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Erectile Dysfunction - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H1 2016', provides an overview of the Erectile Dysfunction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction - The report reviews pipeline therapeutics for Erectile Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Erectile Dysfunction therapeutics and enlists all their major and minor projects - The report assesses Erectile Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Erectile Dysfunction Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Erectile Dysfunction Overview 10 Therapeutics Development 11 Pipeline Products for Erectile Dysfunction - Overview 11 Pipeline Products for Erectile Dysfunction - Comparative Analysis 12 Erectile Dysfunction - Therapeutics under Development by Companies 13 Erectile Dysfunction - Therapeutics under Investigation by Universities/Institutes 16 Erectile Dysfunction - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Erectile Dysfunction - Products under Development by Companies 21 Erectile Dysfunction - Products under Investigation by Universities/Institutes 23 Erectile Dysfunction - Companies Involved in Therapeutics Development 24 Acorda Therapeutics, Inc. 24 Apricus Biosciences, Inc. 25 Biopharm GmbH 26 Corridor Pharmaceuticals Inc. 27 Futura Medical Plc 28 Hanmi Pharmaceuticals, Co. Ltd. 29 Humanetics Corporation 30 IntelGenx Corp. 31 Mezzion Pharma Co. Ltd. 32 Mitsubishi Tanabe Pharma Corporation 33 Monosol Rx, LLC 34 NAL Pharmaceuticals Ltd. 35 Pacific Therapeutics Ltd. 36 Palatin Technologies, Inc. 37 Pharmicell Co., Ltd. 38 Sihuan Pharmaceutical Holdings Group Ltd. 39 Suda Ltd 40 U.S. Stem Cell, Inc. 41 Yungjin Pharm. Co., Ltd. 42 Erectile Dysfunction - Therapeutics Assessment 43 Assessment by Monotherapy Products 43 Assessment by Combination Products 44 Assessment by Target 45 Assessment by Mechanism of Action 48 Assessment by Route of Administration 50 Assessment by Molecule Type 52 Drug Profiles 54 (PDE-5 Inhibitor + tramadol hydrochloride) - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 AdipoCell - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 alprostadil - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 AP-102 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 avanafil - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 BIO-300 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 BL-214 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 cimaglermin alfa - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 fadanafil - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 HCP-1302 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 HCP-1303 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Immpocellgram - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 MED-2005 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 nitroglycerin - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Recombinant Protein for Degenerative Disc Disease, Bone Fracture, Parkinson's Disease and Erectile Dysfunction - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 sildenafil citrate - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 sildenafil citrate - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 sildenafil citrate - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 SUD-003 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 T-6932 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 tadalafil - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 tadalafil - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 tadalafil - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 TF-0092 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 TPN-171 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 TPN-729 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 TR-399 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 udenafil - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 VLFIA-330 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 YBH-1603 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Erectile Dysfunction - Recent Pipeline Updates 96 Erectile Dysfunction - Dormant Projects 109 Erectile Dysfunction - Discontinued Products 112 Erectile Dysfunction - Product Development Milestones 113 Featured News & Press Releases 113 Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity 113 Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting 113 Nov 03, 2014: Auxilium Pharmaceuticals To Present STENDRA Data At SMSNA Scientific Meeting 114 Sep 18, 2014: VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity 114 Jul 09, 2014: New Grant Enables Humanetics to Evaluate Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients 115 Apr 11, 2014: VIVUS To Present Clinical Data On Avanafil at European Association of Urology 116 Feb 24, 2014: IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm Tadalafil Product 116 Jan 21, 2014: VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (avanafil) 116 Aug 01, 2013: VIVUS Announces Commercial Supply Agreement With Sanofi to Produce Avanafil 117 Jun 26, 2013: Vivus Announces European Approval For Spedra For Treatment Of Erectile Dysfunction 117 Appendix 120 Methodology 120 Coverage 120 Secondary Research 120 Primary Research 120 Expert Panel Validation 120 Contact Us 120 Disclaimer 121
List of Tables Number of Products under Development for Erectile Dysfunction, H1 2016 11 Number of Products under Development for Erectile Dysfunction - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Development by Companies, H1 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Development, H1 2016 19 Comparative Analysis by Unknown Stage Development, H1 2016 20 Products under Development by Companies, H1 2016 21 Products under Development by Companies, H1 2016 (Contd..1) 22 Products under Investigation by Universities/Institutes, H1 2016 23 Erectile Dysfunction - Pipeline by Acorda Therapeutics, Inc., H1 2016 24 Erectile Dysfunction - Pipeline by Apricus Biosciences, Inc., H1 2016 25 Erectile Dysfunction - Pipeline by Biopharm GmbH, H1 2016 26 Erectile Dysfunction - Pipeline by Corridor Pharmaceuticals Inc., H1 2016 27 Erectile Dysfunction - Pipeline by Futura Medical Plc, H1 2016 28 Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 29 Erectile Dysfunction - Pipeline by Humanetics Corporation, H1 2016 30 Erectile Dysfunction - Pipeline by IntelGenx Corp., H1 2016 31 Erectile Dysfunction - Pipeline by Mezzion Pharma Co. Ltd., H1 2016 32 Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 33 Erectile Dysfunction - Pipeline by Monosol Rx, LLC, H1 2016 34 Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd., H1 2016 35 Erectile Dysfunction - Pipeline by Pacific Therapeutics Ltd., H1 2016 36 Erectile Dysfunction - Pipeline by Palatin Technologies, Inc., H1 2016 37 Erectile Dysfunction - Pipeline by Pharmicell Co., Ltd., H1 2016 38 Erectile Dysfunction - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 39 Erectile Dysfunction - Pipeline by Suda Ltd, H1 2016 40 Erectile Dysfunction - Pipeline by U.S. Stem Cell, Inc., H1 2016 41 Erectile Dysfunction - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 42 Assessment by Monotherapy Products, H1 2016 43 Assessment by Combination Products, H1 2016 44 Number of Products by Stage and Target, H1 2016 46 Number of Products by Stage and Mechanism of Action, H1 2016 49 Number of Products by Stage and Route of Administration, H1 2016 51 Number of Products by Stage and Molecule Type, H1 2016 53 Erectile Dysfunction Therapeutics - Recent Pipeline Updates, H1 2016 96 Erectile Dysfunction - Dormant Projects, H1 2016 109 Erectile Dysfunction - Dormant Projects (Contd..1), H1 2016 110 Erectile Dysfunction - Dormant Projects (Contd..2), H1 2016 111 Erectile Dysfunction - Discontinued Products, H1 2016 112
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
